Captopril

2. British Cardiac Society Guidelines and Medical Practice Committee, and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Guidelines for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart 2001; 85: 13342. Faulding Pharmaceuticals. Glyceryl trinitrate for injection 5mg 1ml. In: ABPI compendium of data sheets and summaries of product characteristics. ; . London: Datapharm Publications; 1999. p442. 4. Schwarz Pharma. Isoket 0.05 per cent. In: ABPI compendium of data sheets and summaries of product characetristics. London: Datapharm Publications; 1999. pp15001. 5. National Institute for Clinical Excellence. Guidance on the use of glycoprotein IIb IIIa inhibitors in the treatment of acute coronary syndromes.Technology Appraisal Guidance No. 12. London: NICE; 2000. 6. Opie L, Gersh B. Drugs for the heart. Philadelphia: WB Saunders; 2001. 7. British National Formulary Number 42. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2001. 8. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIMECHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000; 2: 20912. Yusuf S, Sleight P, Pogue J, Davies R, Dagenais G. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients.The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med 2000; 342: 14553. Department of Health. National Service Framework for Coronary Heart Disease. London: DoH; 2000 11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia The CURVES study ; .Am J Cardiol 1998; 81: 5827. Wooten JM, Swett Wooten R. Hypolipidaemic drugs. In: Anderson P, Knoben J, Troutman W editors ; . Handbook of clinical drug data. Stamford: Appleton and Lange; 1999. pp36770. 13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324: 7186. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494502. Bazire S. Psychotropic drug directory 2000. Dinton: Mark Allen Publishing; 2000. 16. Internet Mental Health. mentalhealth drug p30-p02 accessed 15 January 2002. 17. Scottish Intercollegiate Guideline Network SIGN ; . Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction. Edinburgh: SIGN; 1999. 18. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the losartan heart failure survival study ELITE II. Lancet 2000; 355: 1582-87. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC AHA ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice Guidelines and policy conferences committee to develop guidelines for the management of patients with atrial fibrillation ; Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Coll Cardiol 2001; 38: 1266. Sanofi Winthrop. Cordarone X 100, Cordarone X 200. In: ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications; 1999. pp13901. 23. Souhami R, Moxham J.Textbook of Medicine. London: Churchill Livingstone; 1990. 53. Establishment of a us-eu-japan three-region clinical development system aims to reduce drug development periods, for example, captopril action. Infection severity could be attributable to some unrecognized genotypic difference between the parent and the other two viruses in a region distant from the LAT. There was, however, no evidence for any genotypic differences besides the LAT promoter deletion ; between the mutant 333pLATand strain 333pLAT R, derived from it, and no phenotypic differences between these two strains except in rates of spontaneous recurrence. These data show that HSV-2 LAT expression influences spontaneous recurrence rates of latent virus. The LATs also appear to play a role in HSV-1 recurrence. While the primary infections of HSV-1 and HSV-2 in humans are indistinguishable, HSV-1 recurs most frequently from primary infections involving the trigeminal dermatome and latent HSV-2 recurs most frequently from sacral ganglia 2 ; . This observation suggests that these viruses differ in their ability to either establish or reactivate from latent infections in a site-specific manner. Because the major LAT sequences of these viruses share essentially random homology, it is possible that the LATs of these viruses have evolved to facilitate reactivation in specific cellular environments. The development of a ganglionic reactivation into a mucocutaneous recurrence involves many factors including viral replication in neurons, peripheral replication, and the immune system. While deletion or mutation of other viral genes e.g., thymidine kinase, ICP0 ; reduces recurrence frequency in some models, identifiable effects of those mutations on the growth and spread of virus has precluded making firm conclusions about their effect on reactivation. In contrast, deletion of sequences from the HSV-2 LAT promoter did not affect neuronal or nonneuronal replication either in vitro or in vivo in immunocompetent guinea pigs. Thus, our findings assign a role to the LAT in reactivation of latent HSV-2. Further study of interactions between the LAT and other viral and cellular genes will be required to precisely establish the mechanisms of HSV reactivation, and how LAT modulates disease. The biopsy results from this first of six trial participants showed both the successful engraftment in the patient's bone marrow of the enzo engineered cells and that they were spawning new differentiated cd4 + cells designed to fight the hiv by continuing to manufacture the required medicine needed by the cells, because captopril kidney. BUSULFEX . 12 BYETTA . 19 cabergoline. 33 calcitonin-salmon spray. 31 calcitriol . 41 calcitriol inj. 41 CALCITRIOL inj . 41 CAMPATH . 13 CAMPRAL . 27 CAMPTOSAR . 14 CANASA . 35 captopril. 24 captopril hydrochlorothiazide . 22, 24 CARAC . 27 CARAFATE susp. 29 carbamazepine. 8 CARBATROL. 8 carbidopa levodopa . 15 carbidopa levodopa ext-rel . 15 carbinoxamine pseudoephedrine 1 mg 15 mg per mL. 38 carboplatin . 14 CARDIZEM CD 360 mg . 22 carisoprodol. 40 CASODEX . 33 CATAPRES-TTS . 19, 21 CEENU . 12 cefaclor . 6 cefadroxil . 6 cefadroxil susp . 6 cefazolin inj . 6 cefoxitin inj . 6 cefpodoxime proxetil. 6 cefprozil . 6 CEFTIN susp . 6 ceftriaxone . 6 cefuroxime axetil. 6 cefuroxime inj . 6 CEFUROXIME SODIUM . 6 CELEBREX .5, 11 CELLCEPT . 35 CELONTIN . 8 CENESTIN . 32 cephalexin . 6 CEREZYME. 28 chloroquine. 14 chlorpheniramine pseudoephedrine ext-rel 8 mg 120 mg . 38 chlorpromazine . 10, 16 45. The treatment effect was statistically significant, individual comparisons were carried out by Fisher's protected least significant difference test. Statistical significance was achieved at P 0.05 24 ; . RESULTS -- Basal blood pressure was minimally decreased during ACE inhibitor treatment Table 1 ; in the type 1 diabetic patients, with a statistically significant effect obtained with enalapril for diastolic values P 0.047 ; . Control A had lower arterial blood pressure systolic pressure 118 2.2 mmHg, diastolic pressure 69 1.9 mmHg ; than placebo-treated type 1 diabetic patients P 0.05 ; , whereas, after ACE inhibition, no statistically significant difference was detected between patients and control group B systolic pressure 117 2.7 mmHg, diastolic pressure 67 1.5 mmHg ; . Basal heart rate was not affected by either captopril or enalapril Table 1 ; . Metabolic control as assessed by fructosamine, plasma glucose during the hemodynamic test, and microalbuminuria was also similar during the three treatments Table 1 ; . ACE inhibition in the patients was associated at baseline with a decrease in femoral artery diameter 8.28 0.29, 7.93 and 7.96 0.17 mm for placebo, captopril, and enalapril groups, respectively; P 0.05 for both captopril and enalapril versus placebo ; . Femoral artery diameter of control A 8.28 0.21 mm ; and control group B 7.92 0.21 mm ; was similar to type 1 diabetic patients after placebo and ACE inhibitor treatment, respectively. Distal postischemic hyperemia elicited similar increases in blood flow velocity in the type 1 diabetic patients after the three treatments placebo 20.0 3.0, captopril 20.5 2.0, enalapril 25.8 1.4 cm s, NS ; , thereby exposing femoral endothelium to comparable stimuli in all occasions. In control subjects, postischemic acceleration of blood flow control A 14.4 1.7 cm s, control group B 16.9 3.7 cm s ; was not statistically different from type 1 diabetic patients treated with either placebo or ACE inhibitors. Changes in femoral artery diameter at each time point during the vascular tests are reported in Table 2. Endothelium-dependent femoral artery response and the endothelial indexes were significantly reduced in the placebo-treated type 1 diabetic patients compared with control A P 0.01 for all groups ; Figs. 1 and 2 ; . Endothelium-independent vasodilation was somewhat but not significantly P 0.11 ; Fig. 3 and diltiazem.
A healthy body makes more white blood cells and sends them to the area where they're needed to fight infection, so eliminating some that have made their way to the wound opening just isn't that critical.

Captopril prescription It is now well established that the pial vascular system and the intracerebral vessels receive an ample supply of sympathetic adrenergic nerves 1, 2 ; . In comparison with other vascular beds, this supply is very pronounced in terms of the number of axon terminals relative to the local amount of smooth musculature in a given portion of the vessel wall. Chemical determinations on pial vascular tissue 3 ; have confirmed the presence of norepinephrine in amounts corresponding to those reported for well-innervated peripheral arterial vessels 4 ; . Ultrastructurally, the neuromuscular complex fulfills accepted morphological criteria for true sympathetic vascular innervation both at the level of the extracerebral 5 ; and the intracerebral 6 ; arterial system. Functionally, it has been shown in experiments with tyramine 7 ; and electric field and doxazosin, for instance, renal artery stenosis captopril. Expedited delivery time is negotiated between contractor and ordering agency overnight and 2 day delivery. CALCIUM TAB 625 MG CALCIUM TAB 835 MG CALCIUM TAB EFF CALCIUM TAB EFF CALCIUM W VITAMINS TAB EFF CANDESARTAN CILEXETI TAB 16 MG CANDESARTAN CILEXETI TAB 8 MG CAPECITABINE FILM-COAT TB 500 MG CAPSICUM TINCT 450 ML ; CAPTOPRIL TAB 12.5 MG CAPTOPRIL TAB 25 MG and mesylate.

Captopril cream Anna Jonsson is a HANS member and a health and safety advisor who researches extensively on various environmental health issues. If you want to comment on the issue of dental amalgam, messages can be left for Anna through the HANS office at 604 ; 435-0512 or you can email her at info hans. NovoLog and NovoLog Mix 70 30 are registered trademarks of Novo Nordisk A S. Humalog and Humalog Mix75 25 are registered trademarks of Eli Lilly and Company. Lantus is a registered trademark of Aventis Pharmaceuticals, Inc and catapres. Ronquist et al. Cohort and Nested Case-Control Analysis patients whose duration of treatment was shorter than 2 years and long-term users were patients treated for a period longer than 2 years. We manually reviewed all computerised medical records among captopril current users to assign the specific indication of use into treatment for hypertension or treatment for IHD and or HF. RESULTS We found an overall incidence rate of prostate cancer of 1.61 95% CI: 1.521.72 ; per 1, 000 personyears among male patients aged 5079 years old. The incidence rate increased markedly with age Fig. 1 ; . None of the variables shown in Table I were significantly associated with the risk of prostate cancer, except antecedents of prostatism. Patients with a history of benign prostatic hyperplasia and or prostatism carried a two-fold greater risk of prostate cancer than those without such antecedents. IHD was not associated with prostate cancer OR: 1.0; 95% CI: 0.81.2 ; , nor other co-morbidities such as diabetes, hypertension or HF. Table II presents the risk of developing prostate cancer associated with use of different classes of antihypertensive drugs. Current use of alpha-blockers was associated with a relative risk close to four compared to no users. This increased risk disappeared when the indication for alpha-blockers was other than prostatism OR: 0.8; 95% CI: 0.41.6 ; . No association was found for all other classes of studied cardiovascular drugs. We explored a duration response effect for the different classes of cardiovascular drugs with no clear pattern of either increased or reduced risk of prostate cancer data not shown ; . In Table III, we report the risk of prostate cancer associated with current use of the most frequently prescribed individual antihypertensive drugs. All estimates were compatible with either a slightly increased or reduced risk. Captoprip was associated with the smallest estimate of risk 0.7 95% CI.

49 comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive type 2 diabetic patients: a double-blind crossover study and cefaclor. Ike other syndromes affecting the lower genital tract of women, vulvovaginal candidiasis has been regarded as more of a "nuisance infection" than a topic of serious scientific inquiry. New advances in molecular epidemiology, host mucosal immunology, and antifungal treatment have, however, enlivened investigation into this common condition. Furthermore, the economic costs of vulvovaginal candidiasis treatment have been well documented, along with the extent to which women treat themselves with a variety of antifungal preparations that are available without a prescription. In 2002 women in the United States spent over half a billion dollars on medications to treat vulvovaginal candidiasis, with about half this amount spent on over the counter preparations.1 This is despite the fact that many women may wrongly diagnose vulvovaginal candidiasis and may be equally or more likely to have bacterial vaginosis, with or without vulvovaginal candidiasis.2 Truly representative data on the epidemiology of vulvovaginal candidiasis are hard to come by. Vaginal colonisation with Candida, a prerequisite for development of vulvovaginal candidiasis, occurs in at least 40% of adult women at any given point and possibly in most women at some time during their adult life.3 Most experts agree that at least half of women will have one episode of vulvovaginal candidiasis by the time they reach their mid-20s.4 A minority of these women--up to 25%--will also have recurrent vulvovaginal candidiasis, defined as four or more episodes a year. Unlike women who have sporadic, uncomplicated vulvovaginal candidiasis, those with recurrent disease do not enjoy the prospect of decreasing frequency of attacks as they age. The pathogenesis of recurrent vulvovaginal candidiasis among women who have no apparent predisposing condition such as poorly controlled diabetes, systemic immunosuppression or immunodeficiency, and use of antibiotics ; is under investigation. The pathogenesis of recurrent disease probably involves some breakdown of the normal mucosal immune processes that allow for mucosal "tolerance" to the organism.5 The emergence of increasingly resistant Candida species does not seem to play a major part in recurrent vulvovaginal candidiasis, although, as a group, women with recurrent disease do have a slightly higher prevalence 10-15% ; of C glabrata, which is inherently less sensitive to the imidazole group of drugs.6 The role of specific behaviours as risk factors for recurrent vulvovaginal candidiasis is unclear, but, for example, captopril renal. Knott PD, Thorpe SS, Lamont CAR. Congenital renal dysgenesis possibly due to captopril. Lancet 1989; 1: 451. Knudsen LB. No association between Griseofulvin and conjoined twinning. Lancet 1987; 1: 1097. Kobayashi H, Kamada S, Shimpo K et al. Teratological study of orally administered fenofibrate in rats. Yakuri to Chiryo 1995; 23 S ; : 983-999. Kobayashi H, Kamada S, Shimpo K et al. Peri- and postnatal study of orally administered fenofibrate in rats. Yakuri to Chiryo 1995; 23 S ; : 1001-1016. Kobayashi N, Matsui I, Tanimura N, Nagahara N et al. Childhood neuroectodermal tumours and malignant lymphoma after maternal ovulation induction. Lancet 1991; 2: 955. Koch S, Hartmann AM, Jager-Roman E, et al. Major malformations in children of epileptic parents due to epilepsy o rite therapy? In: Epilepsy, Pregnancy, and the Child. JAnz D, Dam M, Richens A, et al. Es. Raven Press, New York, 1982. Koch S, Losche G, Jager-Roman et al. Major and minor birth malformations and antiepilectic drugs. Neurology 1992; 42 S ; : 8-88. Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40: 1237-1243. Kochhar DM, Christian MS. Tretinoin: a review of the nonclinical developmental toxicology experience. J Acad Dermatol 1997; 36: 4759. Kochlar DM. Cellular basis of congenital limb deformity induced in mice by vitamin A. Birth Defects Orig Artic Ser 1977; 13: 111-154. Kock HCLV, Merkus JMWM. Graves' disease during pregnancy. Eur J Obstet Gynecol Reprod Biol 1983; 14: 323-330. Koda S, Anabuki K, Miki T, et al. Reproductive studies on cholestyramine. 2. Teratogenicity study in rats. Kiso To Rinsho 1982; 6: 2050-2069. Koda S, Anabuki K, Miki T, et al. Reproductive studies on cholestyramine. 3.teratogenicity study in rabbits. Kiso To Rinsho 1982; 6: 2070-2077. Kodama N, Tsubota K, Ezumi Y. Reproductive studies of lisuride hydrogen maleate: Kiso to Rinsho 1981; 15: 2299-2310 Kofinas AD, Simon NV, Sagel H et al. Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure. J Obstet Gynecol 1991; 165: 630-631. Kohn FE, Kay DL, Cervenka H, et al. Reproduction studies in guinea pigs and rabbits following clothiapine administration. Toxicol Appl Pharmacol 1969; 14: 641. Koizumi K, Aono T. Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 1986; 46: 312-314. Komai Y, Itoh I, Iriyam K et al. Reproduction study of mesnateratogenicity study in rats by intravenous administration. Kiso to Rinsho 1990A; 24: 6563-6594 and cefuroxime.
Now available to detect renal artery stenosis and several tests designed to predict the physiologic significance of the stenotic lesion, the index of clinical suspicion for RVHT remains the focal point of the work-up for RVHT. A brief duration of moderately severe hypertension is the most important clue directing subsequent work-up for RVHT. If the index of clinical suspicion see Fig. 3-14 ; is high, it is reasonable to proceed directly to formal renal arteriography with renal vein renin determination. Alternatively, in patients highly suspected to have RVHT, a captopil renogram followed by a renal arteriogram may be recommended. Strong arguments against RVHT include 1 ; long duration more than 5 years ; of hypertension, 2 ; old age, 3 ; generalized atherosclerosis, 4 ; increased serum creatinine, and 5 ; a normal serum potassium concentration. For these patients, particularly if the blood pressure is only minimally elevated or easily controlled with one or two antihypertensive medications, further work-up for RVHT is not indicated. Adapted from Mann and Pickering [8]; with permission.
Last year, the national institutes of health reported on developments in the treatment of the c virus and citalopram.
10. Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, Hirakawa Y, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002; 290: 909 Matoba T, Shimokawa H, Morikawa K, Kubota H, Kunihiro I, UrakamiHarasawa L, Mukai Y, Hirakawa Y, Akaike T, Takeshita A. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol. 2003; 23: 1224 Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Goto M, Ogasawara Y, Kajiya F. Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo. Circulation. 2003; 107: 1040 Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003; 92: e31 e40. 14. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, Hatanaka M, Fujiki T, Maeda H, Takahashi S, Takeshita A. Pivotal role of Cu, Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 2003; 112: 18711879. Pieper GM, Siebeneich W. Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur J Pharmacol. 2000; 403: 129 Mukai Y, Shimokawa H, Higashi M, Morikawa K, Matoba T, Hiroki J, Kunihiro I, Talukder HM, Takeshita A. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol. 2002; 22: 14451450. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997; 29: 286 Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension. 2000; 36: 575580. Vanhoutte PM. Endothelium-dependent responses and inhibition of angiotensin-converting enzyme. Clin Exp Pharmacol Physiol. 1996; 23: S23S29. 20. Feletou M, Vanhoutte PM. EDHF: new therapeutic targets? Pharmacol Res. 2004; 49: 565580. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997; 100: 27932799. Arakawa M, Sasaki M, Ohmori M, Harada K, Fujimura A. Pharmacokinetics and pharmacodynamics of temocapril during repeated dosing in elderly hypertensive patients. Eur J Clin Pharmacol. 2001; 56: 775779. Shioya H, Shimojo M, Kawahara Y. Determination in plasma of angiotensin-converting enzyme inhibitor by inhibitor-binding assay. J Chromatogr. 1991; 568: 309 Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004; 94: 385393. Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem. 1971; 44: 276 Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW, Jr. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal Biochem. 1990; 184: 193199. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M. Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br J Pharmacol. 2001; 132: 10351046. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of catopril and ramiprilat in hypertension. Hypertension. 1992; 19: 138 Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new trend. Circulation. 1996; 94: 240 de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension. 2001; 38: 1130.